Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.05M | $13.7M | $31.9M | $20.5M | $90.7M | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M |
| Revenue growth | — | 126.8% | 132.6% | -35.7% | 341.9% | -71.8% | -22.8% | 296.3% | -58.6% | 25.4% |
| Operating income | -$97.2M | -$120M | -$114M | -$141M | -$135M | -$193M | -$226M | -$169M | -$251M | -$160M |
| Operating margin | -1605.6% | -873.6% | -356.1% | -686.4% | -148.6% | -756.1% | -1146.3% | -216.6% | -777.2% | -394.9% |
| Net income | -$97.2M | -$120M | -$110M | -$134M | -$116M | -$193M | -$220M | -$153M | -$237M | -$160M |
| Net margin | -1605.5% | -876.5% | -344.3% | -651.4% | -127.8% | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% |
| EPS (diluted) | -$3.02 | -$2.98 | -$2.33 | -$2.68 | -$1.98 | -$2.85 | -$3.21 | -$2.02 | -$2.88 | -$1.80 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$50.2M | -$9.42M | -$45.7M | -$40.7M | -$180M | -$164M | -$177M | -$132M | -$210M | -$165M |
| Capital expenditures | $3.49M | $2.06M | $4.75M | $6.17M | $7.16M | $7.98M | $4.12M | $4.72M | $8.83M | $607K |
| Free cash flow | -$53.7M | -$11.5M | -$50.5M | -$46.8M | -$187M | -$172M | -$181M | -$137M | -$219M | -$166M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $185M | $147M | $135M | $238M | $140M | $204M | $142M | $124M | $132M | $147M |
| Total assets | $229M | $373M | $420M | $509M | $573M | $677M | $514M | $499M | $342M | $187M |
| Total liabilities | $94.6M | $165M | $184M | $246M | $179M | $124M | $154M | $150M | $207M | $159M |
| Long-term debt | — | — | — | — | — | — | — | $0.00 | $52.4M | $53.6M |
| Shareholders' equity | $135M | $208M | $236M | $262M | $394M | $554M | $361M | $349M | $134M | $27.3M |
| Retained earnings | -$186M | -$306M | -$416M | -$549M | -$665M | -$858M | -$1.08B | -$1.23B | -$1.47B | -$1.63B |
| Shares (wtd avg diluted) | 35.8M | 44.5M | 48.8M | 50.0M | 58.6M | 67.6M | 68.7M | 76.0M | 82.3M | 88.7M |
Every figure is extracted from Editas Medicine, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.